publication venue for
- Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. 40:1488-1502.e7. 2022
- Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. 40:1521-1536.e7. 2022
- A tumor "personality" test to guide therapeutic decision making.. 39:747-749. 2021
- A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. 36:51-67.e7. 2019
- Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. 34:483-498.e5. 2018
- The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. 33:905-921.e5. 2018
- The Integrated Genomic Landscape of Thymic Epithelial Tumors. 33:244-258.e10. 2018
- Intertumoral Heterogeneity within Medulloblastoma Subgroups. 31:737-754.e6. 2017
- Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. 31:549-562.e11. 2017
- Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. 30:891-908. 2016
- GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia. 29:61-74. 2016
- VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. 28:210-224. 2015
- Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. 22:425-437. 2012
- Lunatic Fringe Deficiency Cooperates with the Met/Caveolin Gene Amplicon to Induce Basal-like Breast Cancer. 21:626-641. 2012
- Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. 20:143-157. 2011
- Cell of Origin in AML: Susceptibility to MN1-Induced Transformation Is Regulated by the MEIS1/AbdB-like HOX Protein Complex. 20:39-52. 2011
- Che-1 Promotes Tumor Cell Survival by Sustaining Mutant p53 Transcription and Inhibiting DNA Damage Response Activation. 18:122-134. 2010
- Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53. 17:523-523. 2010
- Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53. 17:273-285. 2010
- Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. 10:191-202. 2006
- Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. 6:159-170. 2004
- VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. 4:263-275. 2003
- Getting oncolytic virus therapies off the ground. 4:7-11. 2003